133 related articles for article (PubMed ID: 20566349)
1. In vitro antiviral activity of single domain antibody fragments against poliovirus.
Thys B; Schotte L; Muyldermans S; Wernery U; Hassanzadeh-Ghassabeh G; Rombaut B
Antiviral Res; 2010 Aug; 87(2):257-64. PubMed ID: 20566349
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Poliovirus Neutralization Escape Mutants of Single-Domain Antibody Fragments (VHHs).
Schotte L; Thys B; Strauss M; Filman DJ; Rombaut B; Hogle JM
Antimicrob Agents Chemother; 2015 Aug; 59(8):4695-706. PubMed ID: 26014941
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action and capsid-stabilizing properties of VHHs with an in vitro antipolioviral activity.
Schotte L; Strauss M; Thys B; Halewyck H; Filman DJ; Bostina M; Hogle JM; Rombaut B
J Virol; 2014 Apr; 88(8):4403-13. PubMed ID: 24501405
[TBL] [Abstract][Full Text] [Related]
4. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
Tijsma A; Thibaut HJ; Spieser SA; De Palma A; Koukni M; Rhoden E; Oberste S; Pürstinger G; Volny-Luraghi A; Martin J; Marchand A; Chaltin P; Neyts J; Leyssen P
Antiviral Res; 2014 Oct; 110():1-9. PubMed ID: 25043639
[TBL] [Abstract][Full Text] [Related]
5. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond.
Thys B; De Palma AM; Neyts J; Andries K; Vrijsen R; Rombaut B
Antiviral Res; 2008 Jun; 78(3):278-81. PubMed ID: 18294707
[TBL] [Abstract][Full Text] [Related]
6. Five of Five VHHs Neutralizing Poliovirus Bind the Receptor-Binding Site.
Strauss M; Schotte L; Thys B; Filman DJ; Hogle JM
J Virol; 2016 Jan; 90(7):3496-505. PubMed ID: 26764003
[TBL] [Abstract][Full Text] [Related]
7. 6-(3,4-Dichlorophenoxy)-3-(ethylthio)-2-pyridincarbonitrile inhibits poliovirus uncoating.
González ME; Almela MJ; Yacout M; Carrasco L
Antimicrob Agents Chemother; 1990 Jun; 34(6):1259-61. PubMed ID: 2168147
[TBL] [Abstract][Full Text] [Related]
8. Identification and Analysis of Antiviral Compounds Against Poliovirus.
Leyssen P; Franco D; Tijsma A; Lacroix C; De Palma A; Neyts J
Methods Mol Biol; 2016; 1387():325-38. PubMed ID: 26983743
[TBL] [Abstract][Full Text] [Related]
9. Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains.
Duan L; Zhang H; Oakes JW; Bagasra O; Pomerantz RJ
Hum Gene Ther; 1994 Nov; 5(11):1315-24. PubMed ID: 7893803
[TBL] [Abstract][Full Text] [Related]
10. A simple quantitative affinity capturing assay of poliovirus antigens and subviral particles by single-domain antibodies using magnetic beads.
Thys B; Saerens D; Schotte L; De Bleeser G; Muyldermans S; Hassanzadeh-Ghassabeh G; Rombaut B
J Virol Methods; 2011 May; 173(2):300-5. PubMed ID: 21371506
[TBL] [Abstract][Full Text] [Related]
11. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.
Kouiavskaia DV; Dragunsky EM; Liu HM; Oberste MS; Collett MS; Chumakov KM
Antivir Ther; 2011; 16(7):999-1004. PubMed ID: 22024515
[TBL] [Abstract][Full Text] [Related]
12. D-5-Chloro-2-(alpha-hydroxybenzyl) benzimidazole and 1-alkyl-5-chloro-2-(alpha-hydroxybenzyl) benzimidazoles as inhibitors of poliovirus multiplication.
O'Sullivan DG; Pantic D; Wallis AK
Experientia; 1968 Jul; 24(7):661-3. PubMed ID: 4303116
[No Abstract] [Full Text] [Related]
13. Antiviral activity of aqueous and ethanol extracts and of an isolated polysaccharide from Agaricus brasiliensis against poliovirus type 1.
Faccin LC; Benati F; Rincão VP; Mantovani MS; Soares SA; Gonzaga ML; Nozawa C; Carvalho Linhares RE
Lett Appl Microbiol; 2007 Jul; 45(1):24-8. PubMed ID: 17594456
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.
Salvati AL; De Dominicis A; Tait S; Canitano A; Lahm A; Fiore L
Antimicrob Agents Chemother; 2004 Jun; 48(6):2233-43. PubMed ID: 15155227
[TBL] [Abstract][Full Text] [Related]
15. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae.
Conrath KE; Lauwereys M; Galleni M; Matagne A; Frère JM; Kinne J; Wyns L; Muyldermans S
Antimicrob Agents Chemother; 2001 Oct; 45(10):2807-12. PubMed ID: 11557473
[TBL] [Abstract][Full Text] [Related]
16. Effect of D-penicillamine on poliovirus replication in HeLa cells.
Merryman P; Jaffe IA; Ehrenfeld E
J Virol; 1974 Apr; 13(4):881-7. PubMed ID: 4362514
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of poliovirus replication by a plant antiviral peptide.
Ussery MA; Irvin JD; Hardesty B
Ann N Y Acad Sci; 1977 Mar; 284():431-40. PubMed ID: 212985
[No Abstract] [Full Text] [Related]
18. Antipoliovirus activity and mechanism of action of 3-methylthio-5-phenyl-4-isothiazolecarbonitrile.
Garozzo A; Stivala A; Tempera G; Castro A
Antiviral Res; 2010 Dec; 88(3):325-8. PubMed ID: 20955736
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Antiviral Activity of New Oxazoline Derivatives as Potent Poliovirus Inhibitors.
Madia VN; Messore A; Pescatori L; Saccoliti F; Tudino V; De Leo A; Scipione L; Fiore L; Rhoden E; Manetti F; Oberste MS; Di Santo R; Costi R
J Med Chem; 2019 Jan; 62(2):798-810. PubMed ID: 30512950
[TBL] [Abstract][Full Text] [Related]
20. An antiviral compound that blocks structural transitions of poliovirus prevents receptor binding at low temperatures.
Dove AW; Racaniello VR
J Virol; 2000 Apr; 74(8):3929-31. PubMed ID: 10729171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
